Nature Reviews Neurology

ICYMI: New online! Sex differences in frontotemporal dementia

Epigenetic clocks and DNA methylation biomarkers of brain health and disease Nature Reviews Neurology - This Review considers how DNA methylation-based biomarkers can be used to monitor brain ageing and stratify neurological disease risk. The authors focus on epigenetic...

Our featured article for August is a Review by Riccardo Marioni and colleagues on epigenetic clocks and DNA methylation biomarkers of brain health and disease - click on this link to access the PDF for free: rdcu.be/eyFSg

Our August issue, which includes articles on artificial intelligence and neurotechnology, CAR T cell therapies for cancer, and multiple sclerosis management, is now live! bit.ly/45eHSt2

A wearable spatiotemporal controllable ultrasonic device with amyloid-β disaggregation for continuous Alzheimer’s disease therapy A portable, fully integrated wearable ultrasound system (WUS) promotes amyloid protein depolymerization.

A wearable spatiotemporal controllable ultrasonic device with amyloid-β disaggregation for continuous Alzheimer’s disease therapy | Science Advances www.science.org/doi/10.1126/...

ICYMI: New online! Dementia research in low-income and middle-income countries — a view from Latin America

Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function This randomized clinical trial assesses the effect of structured vs self-guided multidomain lifestyle interventions on changes in global cognitive function over 2 years among older adults at risk of c...

Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function jamanetwork.com/journals/jam...

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy Objective Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of multiple system atrophy (MSA). We investigated these effects in a proof-.....

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy onlinelibrary.wiley.com/doi/10.1002/...

New online! Dementia research in low-income and middle-income countries — a view from Latin America

Advancing multiple sclerosis management in older adults Nature Reviews Neurology, Published online: 23 July 2025; doi:10.1038/s41582-025-01115-5Approximately half of the people currently with multiple sclerosis (MS) are ≥50 years of age, yet guidelines for management of MS in older age are lacking. This Consensus statement presents the outcomes of an International Advisory Committee on Clinical Trials (IACCT) in MS workshop on ageing and MS, including recommendations for advancing research, care and awareness.

ICYMI: New online! Advancing multiple sclerosis management in older adults

Distinct inflammatory profiles in young‐onset versus late‐onset Alzheimer's disease INTRODUCTION Neuroinflammation, a key player in Alzheimer's disease (AD) pathogenesis, may be differentially involved in young-onset (YOAD) compared to late-onset (LOAD) AD. METHODS Using proximit...

Distinct inflammatory profiles in young‐onset versus late‐onset Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Frontal cortex pyramidal neuron expression profiles differentiate the prodromal stage from progressive degeneration across the Alzheimer's disease spectrum INTRODUCTION Underlying causes of Alzheimer's disease (AD) remain unknown, making it imperative to identify molecular mechanisms driving the pathobiology of AD onset and progression. METHODS Laser...

Frontal cortex pyramidal neuron expression profiles differentiate the prodromal stage from progressive degeneration across the Alzheimer's disease spectrum alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions Nature Reviews Neurology, Published online: 21 July 2025; doi:10.1038/s41582-025-01123-5Here, Rafii and Aisen review recent progress surrounding the approvals of amyloid-targeting monoclonal antibodies, the first disease-modifying therapies for Alzheimer disease. The Review highlights key factors that affect the integration of these treatments into clinical practice and explores future directions.

ICYMI: New online! Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions

ICYMI: New online! Sex differences in frontotemporal dementia

New online! Sex differences in frontotemporal dementia

Advancing multiple sclerosis management in older adults Nature Reviews Neurology, Published online: 23 July 2025; doi:10.1038/s41582-025-01115-5Approximately half of the people currently with multiple sclerosis (MS) are ≥50 years of age, yet guidelines for management of MS in older age are lacking. This Consensus statement presents the outcomes of an International Advisory Committee on Clinical Trials (IACCT) in MS workshop on ageing and MS, including recommendations for advancing research, care and awareness.

ICYMI: New online! Advancing multiple sclerosis management in older adults

Serum Neurofilament Light Chain as a Biomarker in Multiple Sclerosis: A Cross-Sectional Observation in Real-World Clinical Practice Multiple Sclerosis (MS) is a chronic neurological condition characterized by inflammation in the central nervous system, leading to demyelination and neurodegeneration. A hallmark of MS is its unpredi...

Serum Neurofilament Light Chain as a Biomarker in Multiple Sclerosis: A Cross-Sectional Observation in Real-World Clinical Practice www.msard-journal.com/article/S221...

M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development M6A-driven condensation of an intron-containing FUS RNA isoform regulates its splicing and has translational potential in ALS.

M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development | Science Advances www.science.org/doi/10.1126/...

Advancing multiple sclerosis management in older adults Nature Reviews Neurology, Published online: 23 July 2025; doi:10.1038/s41582-025-01115-5Approximately half of the people currently with multiple sclerosis (MS) are ≥50 years of age, yet guidelines for management of MS in older age are lacking. This Consensus statement presents the outcomes of an International Advisory Committee on Clinical Trials (IACCT) in MS workshop on ageing and MS, including recommendations for advancing research, care and awareness.

New online! Advancing multiple sclerosis management in older adults

Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions Nature Reviews Neurology, Published online: 21 July 2025; doi:10.1038/s41582-025-01123-5Here, Rafii and Aisen review recent progress surrounding the approvals of amyloid-targeting monoclonal antibodies, the first disease-modifying therapies for Alzheimer disease. The Review highlights key factors that affect the integration of these treatments into clinical practice and explores future directions.

ICYMI: New online! Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions

Machine learning in Alzheimer’s disease genetics - Nature Communications Here the authors apply machine learning approaches to Alzheimer’s genetics, confirm known associations and suggest novel risk loci. These methods demonstrate predictive power comparable to traditional...

Machine learning in Alzheimer’s disease genetics www.nature.com/articles/s41...

ICYMI: New online! Reply to ‘Perils and pitfalls of near-death experience research’

ICYMI: New online! Perils and pitfalls of near-death experience research

Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions Nature Reviews Neurology, Published online: 21 July 2025; doi:10.1038/s41582-025-01123-5Here, Rafii and Aisen review recent progress surrounding the approvals of amyloid-targeting monoclonal antibodies, the first disease-modifying therapies for Alzheimer disease. The Review highlights key factors that affect the integration of these treatments into clinical practice and explores future directions.

New online! Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions

AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial - Nature Communications Alzheimer’s disease (AD) drug discovery has been hampered by patient heterogeneity, and the lack of sensitive tools for precise stratification. Here, the authors show an AI-guided model enhances patie...

AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial www.nature.com/articles/s41...

MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. T...

MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis jnnp.bmj.com/cgi/content/...

Neurofilament light chain improves clinical prognostic models for Guillain-Barré syndrome Background Several prognostic models predict clinical outcomes in Guillain-Barré syndrome (GBS). Recently, neurofilament light chain (NfL) has emerged as a prognostic biomarker. We investigated the ad...

Neurofilament light chain improves clinical prognostic models for Guillain-Barre syndrome jnnp.bmj.com/cgi/content/...

Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder Nature Reviews Neurology, Published online: 14 July 2025; doi:10.1038/s41582-025-01116-4In this Review, the authors describe perturbations in neuroimmune, metabolic and oxidative pathways in major depressive disorder and explore how imbalances in each of these pathways can contribute to the acute phase of the disease.

ICYMI: New online! Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder

Translating lifestyle interventions for optimal brain health in Africa Nature Reviews Neurology, Published online: 11 July 2025; doi:10.1038/s41582-025-01104-8This Perspective article explores the efficacy of multimodal lifestyle interventions to tackle the rising incidence of dementia in low- and middle-income countries. The authors discuss a contextual adaptation of the Finnish FINGER trial, Africa-FINGERS, which is pioneering a culturally relevant, multidomain approach to dementia risk reduction for African settings.

ICYMI: New online! Translating lifestyle interventions for optimal brain health in Africa

ICYMI: New online! Challenges of combining multimodal data in assessment of people with traumatic brain injury

ICYMI: New online! Perils and pitfalls of near-death experience research